Pharmacy Department, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA.
Ann Pharmacother. 2012 Nov;46(11):1477-83. doi: 10.1345/aph.1R158. Epub 2012 Oct 16.
The risk of vancomycin-associated nephrotoxicity varies greatly depending on the trough concentration. Recent guidelines suggest target vancomycin trough concentrations of 15-20 mg/L as a predictor of efficacy in the treatment of severe gram-positive infections. Limited data exist quantifying the risk for nephrotoxicity with various ranges of vancomycin troughs.
To determine the occurrence of nephrotoxicity during vancomycin therapy and up to 72 hours after its completion, in relation to the maximum trough concentration value, and identify risk factors that impact nephrotoxicity associated with vancomycin use.
We reviewed the medical records of veterans with a baseline serum creatinine less than 2 mg/dL who received 48 or more hours of vancomycin therapy and had 1 or more vancomycin trough samples obtained within 96 hours of therapy initiation from January 1, 2006, to November 1, 2008, to determine the occurrence of nephrotoxicity (as defined by RIFLE [Risk, Injury, Failure, Loss, and End-stage renal disease] criteria).
Thirty-four (12.6%) patients developed nephrotoxicity. In multiple logistic regression analysis, maximum trough concentrations (OR 1.14; 95% CI 1.09 to 1.20), documented hypotension (OR 4.7; 95% CI 1.3 to 16.4), and weight (OR 1.02; 95% CI 1.0 to 1.03) were found to be significantly associated with the occurrence of nephrotoxicity. Once stratified into ranges of 5-10 mg/L (4.9%), 10.1-15 mg/L (3.1%), 15.1-20 mg/L (10.6%), 20.1-35 mg/L (23.6%), and greater than 35 mg/L (81.8%), increasing trough ranges were associated with a subsequently higher risk of nephrotoxicity.
In the population evaluated, hypotension and trough concentrations were predictors of nephrotoxicity; elevated vancomycin trough concentration had the highest odds of association. These data reinforce the close therapeutic monitoring guidelines for vancomycin trough concentrations, especially when targeting troughs of 15-20 mg/L.
万古霉素相关性肾毒性的风险差异很大,这取决于谷浓度。最近的指南建议万古霉素谷浓度目标为 15-20mg/L,作为治疗严重革兰氏阳性感染疗效的预测指标。目前还存在有限的数据来量化各种万古霉素谷浓度范围内肾毒性的风险。
确定万古霉素治疗期间和治疗完成后 72 小时内肾毒性的发生情况,与最大谷浓度值的关系,并确定影响万古霉素相关肾毒性的危险因素。
我们回顾了 2006 年 1 月 1 日至 2008 年 11 月 1 日期间,基线血清肌酐<2mg/dL 的退伍军人的病历,这些患者接受了 48 小时以上的万古霉素治疗,并且在治疗开始后 96 小时内获得了 1 个或多个万古霉素谷样本,以确定肾毒性的发生情况(根据 RIFLE(风险、损伤、衰竭、损失和终末期肾病)标准定义)。
34 名(12.6%)患者发生了肾毒性。在多变量逻辑回归分析中,最大谷浓度(比值比 1.14;95%可信区间 1.09 至 1.20)、记录的低血压(比值比 4.7;95%可信区间 1.3 至 16.4)和体重(比值比 1.02;95%可信区间 1.0 至 1.03)与肾毒性的发生显著相关。一旦分为 5-10mg/L(4.9%)、10.1-15mg/L(3.1%)、15.1-20mg/L(10.6%)、20.1-35mg/L(23.6%)和>35mg/L(81.8%)的范围,谷浓度范围增加与肾毒性风险增加相关。
在评估的人群中,低血压和谷浓度是肾毒性的预测指标;升高的万古霉素谷浓度与关联性最高。这些数据强化了万古霉素谷浓度的密切治疗监测指南,特别是当目标谷浓度为 15-20mg/L 时。